search for
confirm
cancel

News Center

Repeatedly favored by high-quality capital, Borui Pharmaceuticals receives investment

  • Categories:NEW
  • Author:
  • Origin:
  • Time of issue:2019-11-05 12:00
  • Views:0

Repeatedly favored by high-quality capital, Borui Pharmaceuticals receives investment

(Summary description)Recently, Borui Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical") announced the completion of a 550 million yuan Pre-IPO round of financing. This round of financing was jointly led by Sequoia Capital China Fund and Honghui Capital. Stem and participate in investment.

  • Categories:NEW
  • Author:
  • Origin:
  • Time of issue:2019-11-05 12:00
  • Views:0
Information

Borui Medicine

Recently, Borui Biomedical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical") announced the completion of a 550 million yuan Pre-IPO round of financing. This round of financing was jointly led by Sequoia Capital China Fund and Honghui Capital. Stem and participate in investment.

Borui Medicine is a "national high-tech enterprise" founded by Dr. Yuan Jiandong, a specially-appointed expert of the "Thousand Talents Program". It is committed to the development and production of original new drugs and difficult generic drugs, and to find solutions for unmet clinical needs. Borui Pharmaceuticals has developed rapidly based on its strong R & D capabilities, relying on global registration and commercialization capabilities, as well as the internationally-accepted cGMP production quality system, and has achieved rapid development. It has become a comprehensive industrial chain covering R & D, production, and sales. Pharmaceutical Group. Borui Pharmaceutical has set up a research and development team, with annual R & D investment exceeding 20% ​​of operating income; the production quality management system has passed cGMP certification in Europe, the United States, Japan, and South Korea; products such as caspofungin have been listed in the European and American markets; and Ai has been successfully developed Riblin, trabectedin, fondaparinux, and other high-end generic drugs have established product lines with global competitive advantages in anti-tumor, super antibiotics, intravenous iron supplementation and other fields. A number of well-known investment funds including SDIC, CICC, Huatai and others are stationed in it.

The chairman of the company, Yuan Jiandong, said that the funding of this round of financing was mainly used in two aspects: on the one hand, it was invested in the development of innovative drugs and clinical. Before, the company kept some "global new" original candidates. Due to the rolling development of its own business profits, the project progressed slowly. Incremental funding will play a positive role in rapidly advancing the progress of these innovative drugs. On the other hand, part of the funds raised in this round of financing will be used to increase the production capacity of the raw material plant and the construction of the injection plant, which will produce high-end injections for the global market, which will be the company's main source of future profits.

Xu Qiang, vice president of Sequoia Capital China Fund, said, "'Consistent evaluation + centralized procurement' will accelerate the reshuffle of the pharmaceutical industry. We value the company's core values ​​and the competitive advantages formed by technological barriers. Borui Bio focuses on competitors The high-end APIs and preparations with few technical difficulties are clearly positioned; based on multi-chiral drug platforms, fermentation semi-synthetic platforms, abiotic macromolecular platforms, and targeted polymer coupling platforms, a number of technical barriers have been developed and reserved High-quality products; at the same time, it has established a complete industrial chain from difficult intermediates, high-end APIs to pharmaceutical preparations, and has a strong competitive advantage in the future industrial integration. We are optimistic about the long-term development potential and sustainable driving force of Borui Pharmaceutical, and are willing Support the long-term and steady development of such outstanding companies. "

He Xing, a partner of Honghui Capital, said, "We are very happy to cooperate with Sequoia Capital China Fund to invest and serve Borui Pharmaceuticals. Borui Pharmaceuticals is a research and development-driven high-tech pharmaceutical company whose core products are leading in the global market. The management team has rich experience, especially under the leadership of Chairman Yuan Jiandong, which has given full play to the two-wheel drive competitive advantage of core technical capabilities and operational execution capabilities. "

About Sequoia Capital China Fund

Sequoia Capital is always committed to helping entrepreneurs become great companies that have a long history of foundation, bringing rich global resources and valuable historical experience to member companies. For 47 years, Sequoia Capital has invested in many innovative companies and leaders in industry trends. As "the entrepreneur behind entrepreneurs", Sequoia Capital China Fund focuses on investment opportunities in four directions: technology / media, healthcare, consumer goods / services, and industrial technology. For fourteen years, Sequoia Capital China Fund has invested in more than 500 companies with distinctive technical characteristics, innovative business models, and high growth and development potential.

About Honghui Capital

Honghui Capital is an investment fund focused on the medical and health industry. It manages dual currency funds in USD and RMB. Honghui Capital's investment is focused on biomedicine, medical equipment, etc. Investment portfolio includes: Mindray Medical (300760), Yuyue Medical (002223), WuXi AppTec (603259), Hequan Pharmaceutical (832159), Kanglong Chemicals, Pioneer Pharmaceutical, Baiyang Pharmaceutical, Shengxiang Biotechnology, Ma泷 Dental and other high-quality enterprises.

About Guangfa Qianhe

Guangfa Qianhe Investment Co., Ltd. is a wholly-owned alternative investment subsidiary established by Guangfa Securities Co., Ltd. (stock code: 000776.SZ, 1776.HK). Guangfa Qianhe is currently mainly engaged in equity investment business, with industry-leading equity investment scale and capabilities, and is committed to helping high-quality customers grow into leaders in subdivided industries through capital operations.
The pharmaceutical sector is one of Guangfa's leading and key industries. It has invested in a number of high-quality companies such as Qingdao Baiyang, Kanglong Chemical, Kawei Bio, Ocean Pharmaceuticals, and Akang Health.

Back to top ▲

Borui Medicine

address:

Building C25-28, 218 Xinghu Road, Suzhou Industrial Park, Jiangsu Province, China

Borui Medicine

phone:

0512-62620988

 

Borui Medicine

Fax:
0512-62551799

Copyright: Brilliant Biomedical (Suzhou) Co., Ltd. Website: CE Dongli · Suzhou Su ICP No. 18,000,014           

Copyright: Borui Biomedical (Suzhou) Co., Ltd. 

Powered by www.300.cn 

苏ICP备18000014号